Details

Autor(en) / Beteiligte

• Singh, Karnika
• Han, Chunhua
• Fleming, Jessica L
• Becker, Aline P
• McElroy, Joseph
• Cui, Tiantian
• Johnson, Benjamin
• Kumar, Ashok
• Sebastian, Ebin
• Showalter, Christian A
• Schrock, Morgan S
• Summers, Matthew K
• Becker, Valesio
• Tong, Zhen-Yue
• Meng, Xiaomei
• Manring, Heather R
• Venere, Monica
• Bell, Erica H
• Robe, Pierre A
• Grosu, A L
• Haque, S Jaharul
• Chakravarti, Arnab

Titel

TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways

Ist Teil von

• Scientific reports, 2023-08, Vol.13 (1), p.12424-12424

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2023

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• GBM (Glioblastoma) is the most lethal CNS (Central nervous system) tumor in adults, which inevitably develops resistance to standard treatments leading to recurrence and mortality. TRIB1 is a serine/threonine pseudokinase which functions as a scaffold platform that initiates degradation of its substrates like C/EBPα through the ubiquitin proteasome system and also activates MEK and Akt signaling. We found that increased TRIB1 gene expression associated with worse overall survival of GBM patients across multiple cohorts. Importantly, overexpression of TRIB1 decreased RT/TMZ (radiation therapy/temozolomide)-induced apoptosis in patient derived GBM cell lines in vitro. TRIB1 directly bound to MEK and Akt and increased ERK and Akt phosphorylation/activation. We also found that TRIB1 protein expression was maximal during G2/M transition of cell cycle in GBM cells. Furthermore, TRIB1 bound directly to HDAC1 and p53. Importantly, mice bearing TRIB1 overexpressing tumors had worse overall survival. Collectively, these data suggest that TRIB1 induces resistance of GBM cells to RT/TMZ treatments by activating the cell proliferation and survival pathways thus providing an opportunity for developing new targeted therapeutics.